Luciana Gambirasio Souza’s Post

Brazil’s healthcare private system rivals the population of the fifth-largest European country. With 51 million beneficiaries in private health plans, the Brazilian market offers immense opportunities for growth and innovation in the pharmaceutical sector. Looking to expand your business in the pharmaceutical industry? Discover the Brazilian market in just 4 clicks through Pharma Meeting Brazil. It's simple, effective, and a recognized tool in BD&L. #PharmaMeetingBrazil #PharmaceuticalIndustry #BusinessGrowth

🚀 **New Case Study Alert**: Restructuring US Market Access Organization for a Global Pharmaceutical Company In the fast-paced and ever-evolving healthcare sector, facing both external and internal hurdles, a leading global pharmaceutical company recognized the urgent need for a strategic overhaul of its US Market Access organization. This initiative was not just about maintaining a competitive edge; it was about adeptly navigating the complexities of the American healthcare landscape with innovative and forward-thinking solutions. Our newly released case study delves into the strategic roadmap devised and executed to facilitate this bold transformation. "Restructuring US Market Access Organization for a Global Pharmaceutical Company" is a testament to the power of strategic foresight, problem-solving, and a commitment to future-oriented approaches in achieving operational excellence and securing market leadership. 📥 Immerse yourself in the journey of transformation: Discover how blending life sciences expertise with a deep understanding of client culture leads to unparalleled success. #PharmaceuticalLeadership #MarketAccess #StrategicTransformation #LifeSciencesExcellence https://ow.ly/Jhev50RsL7o

𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗙𝗿𝗮𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 The pharmaceutical landscape is increasingly challenged by having multiple payers and varied pricing strategies. This means developing effective pricing and access strategies has become more complex than ever. 𝗞𝗲𝘆 𝗶𝗺𝗽𝗮𝗰𝘁𝘀 𝗼𝗳 𝗳𝗿𝗮𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗲: 🔶Diverse Payer Requirements 🔶Inconsistent Pricing Models 🔶Access Barriers It will be interesting to see which pharmaceutical companies thrive in this environment, and through which strategies. #Pharma #MarketAccess #Healthcare #PricingStrategy #PatientAccess

🌍 Today, on World Health Day, we reflect on the importance of global health and the pivotal role of the pharmaceutical industry in advancing healthcare worldwide. At eQuantX, we are committed to driving innovation and accessibility in healthcare, ensuring that life-saving medications reach those who need them most. We achieve this by providing best-in-class research and consulting solutions to pharmaceutical companies, aiding in the development and commercialization of their innovative medicines. Let's continue to collaborate and innovate, building up the way for a healthier future for all. #WorldHealthDay #PharmaInnovation #HealthForAll #eQuantX🌱💊

Association of the British Pharmaceutical Industry This report highlights the impact of NHS-industry partnerships on patient outcomes. Research shows that hospitals collaborating with industry are significantly more aligned with NICE recommendations for prescribing medicines, leading to better patient care. #NHS #healthcare #partnerships #research #abpi

The long-term care market is currently experiencing a trend of increasing consolidation. By building solid relationships with these key players, pharmaceutical companies can streamline their efforts and meet patients' needs more effectively. As market consolidation continues, the potential for impactful partnerships and growth in this space becomes even more promising. Stay connected with Life Sciences by PointClickCare on LinkedIn for the newest developments and expert content. #LongTermCare #Healthcare #StrategicPartnerships

At Sandoz, we believe that driving biosimilar adoption can support more equitable access to high-quality healthcare and improve outcomes for patients across the globe. We’re excited about the opportunity to foster Day 1 access to generics and biosimilars in Europe, improve supply chain resilience and simplify the regulatory framework with the ongoing EU Pharma Review 🌍 This week, Rebecca Guntern, President Region Europe and Country President Switzerland, and Peter Stenico, Global Head of Biosimilars and Country President Austria, spoke at Reuters Events Pharma where they shared their insights on the importance of revising the EU pharmaceutical legislation, regulatory streamlining, and the adoption of smarter procurement processes to increase access to generics and biosimilars in Europe. See below for some key takeaways from Rebecca and Peter 👇 #Biosimilars #Healthcare #REPharma2024 http://bit.ly/43Qc64c

🔍 Investigating Mark Cuban's Cost Plus Pharmacy: Here's what I discovered When I first heard Mark Cuban launched an online pharmacy, I was skeptical. Another billionaire entering healthcare? But what I found was surprisingly refreshing: 🔹Complete pricing transparency 🔹Significant cost savings on medications 🔹A straightforward pricing model: Drug cost + minimal markup + pharmacy fee = final price Why this matters: The pharmaceutical industry has long operated behind a veil of complex pricing. For the first time, we're seeing exactly what medications actually cost and how pricing is determined. 🤔 Think your medications are expensive? Try checking their prices at https://lnkd.in/gmuhfndm . The transparency alone might surprise you. This isn't just about cheaper drugs - it's about transforming how we think about pharmaceutical pricing in America. Have you checked your medication prices on Cost Plus Drugs? What was your experience? #Pharmaceuticals #MarkCuban #CostPlusDrugs #HealthcarePricing #Transparency #Healthcare #PharmaceuticalIndustry #DrugPricing

GSK and Veradigm partnered on a groundbreaking study published in Therapeutic Innovation & Regulatory Science. This research shows that using a digital, bidirectional communication channel between healthcare professionals and pharmaceutical safety teams can dramatically improve the speed and quality of Adverse Event (AE) reporting at the point of care. Key findings: - 96% faster AE follow-up times - Collection of real-time, HCP-validated AE data - Improved data quality over traditional reporting methods Learn more about the study here. https://okt.to/js6Ln9 #healthcare #HCPs #patients

Save the date !!